Ah, the benefits of private arbitration. Quick and clean decisions by a neutral panel, rendered out of the public spotlight and, in most circumstances, unappealable to a court of law.
So where did things go wrong for Cooley Godward, whose client got smacked this spring with what Cooley calls “a swing of some $30 million” in a dispute involving a drug designed to help patients with blood flow problems that jeopardize their vital organs?
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
